Cytek Biosciences, Inc. (CTKB) fair value analysis
Nasdaq · Updated 2026-09-07
Cytek Biosciences, Inc. develops and manufactures flow cytometry instruments and reagents used in cell analysis and research applications within the life sciences industry. The company operates globally with a presence in multiple regions including North America, Europe, and Asia-Pacific.
Valuation status
Awaiting full valuationCTKB does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $4.31
- Sector
- Healthcare
- 12-month range
- $3.61–$5.33
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- Margin trend
- Contracting
- Revenue growth
- Modest
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The lower-middle quarter of its range
What our data shows for CTKB
- Our model validated 5 trailing price-to-earnings windows for CTKB, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $3.61–$5.33.
- The 14-day relative strength index sits at a neutral 61.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CTKB
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the CTKB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CTKB stock undervalued?
CTKB does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is CTKB's TickrTrends verdict?
CTKB is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is CTKB overbought or oversold?
CTKB's 14-day RSI is in neutral territory - neither overbought nor oversold.